Dividend Win Wednesday: 7.6% FCF Yields, $66M Defense Buys, and Payout Cover

This Week's Setup

After a long stretch of stress, broad fear gauges finally printed a relief read near 29, enough to stop treating every dividend payer as broken. The work that matters is still on cash flow: NVS at a 5.2% FCF yield with a 3.1% dividend, NEM with a 5.8% FCF yield on a 29% ROIC, and BIIB levering a 7.6% FCF yield with 55% insider buying.

The screen also lines up steel at NUE and STLD, defense cash conversion at GD, integrated energy at COP, and GILD on HIV prevention expansion, all with double-digit ROIC or margin profiles that make the dividends look like outcomes of operations, not hopes about the tape.

The 8 Names

1. Novartis AG (NVS)

Stock Pixie Score 9.2/10 | FCF yield 5.2% | Dividend yield 3.1% | 10% drawdown

The setup here is a 5.2% FCF yield covering a 3.1% dividend with 35% cushion (payout cover 1.69), a 19.7% ROIC, and a gross margin of 75.8%. Net debt sits at 1.02× EBITDA, manageable for a pharma with a deep pipeline and $15.3 billion in interest coverage.

Novartis released two-year Phase III APPLAUSE-IgAN data for Fabhalta (iptacopan) in IgA nephropathy, sharpening the commercial case for a therapy that targets complement dysregulation. The dataset strengthens the valuation thesis for a franchise already approved in paroxysmal nocturnal hemoglobinuria.

Analyst consensus sits at $153.26, 7 cents below the current price, and the stock has traded sideways for a year (0.16% trend). The market is pricing in pipeline execution risk, not giving credit for the IgAN opportunity until scripts ramp.

Five-year dividend growth runs at 7.2% CAGR, but currency translation and European policy risk can clip that rate if the euro weakens or pricing pressure accelerates across the EU pharma complex.

2. Newmont Corporation (NEM)

Stock Pixie Score 8.7/10 | FCF yield 5.8% | ROIC 29.2% | 13% drawdown

Newmont prints a 29.2% ROIC, 21.3% revenue growth year-over-year, and a 5.8% FCF yield against an 0.9% dividend yield. The company carries no net debt (net debt/EBITDA of −0.18), giving it balance-sheet optionality to fund buybacks, dividends, or acquisitions without capital-market dependency.

Director Peter Toth added shares on March 20 and again on April 3; CFO David Fry bought on March 18. The three transactions total 8,092 net shares purchased in the last 30 days, a collective $950,000 bet at current prices.

Payout cover is low at 1.79× (5.8% FCF yield divided by 3.2% shareholder yield), leaving limited room for dividend growth unless gold prices hold or operating leverage expands. Management has prioritized buybacks and debt paydown over yield increases in recent quarters.

The analyst target of $139.82 implies 18.9% upside, but that forecast assumes sustained gold prices above $2,700 per ounce and no operational disruption at Tier 1 assets. Geopolitical risk in key jurisdictions (Peru, Ghana) can compress multiples quickly.

3. Biogen Inc. (BIIB)

Stock Pixie Score 8.4/10 | FCF yield 7.6% | Insider buying 55.3% | 13% drawdown

Biogen generates a 7.6% FCF yield, the highest on this screen, with a 75.7% gross margin and $6.8 billion in interest coverage. Net debt/EBITDA of 0.79 is conservative for a biotech with a diversified revenue base across multiple sclerosis, Alzheimer's, and rare disease franchises.

CFO Sean Godbout purchased shares on April 3, adding to a six-month insider-buying wave that totals 83,964 net shares acquired (55.3% buy rate, 2.2% sell rate). That $14.8 million in aggregate insider purchases signals management confidence at current prices.

⬡ Partner Takeda ended its collaboration with Denali Therapeutics this week, a reminder that Biogen's pipeline partnerships carry execution risk. The company's Alzheimer's franchise (Leqembi) faces reimbursement headwinds in the U.S. and slow European uptake, pressuring revenue growth forecasts.

ROIC sits at 6.8%, well below the cost of capital for a large-cap biotech. The market is waiting for pipeline readouts and margin expansion to justify the 20× P/E multiple; another partnership termination or trial failure could send the stock below $160.

4. ConocoPhillips (COP)

Stock Pixie Score 8.2/10 | FCF yield 4.8% | Dividend yield 2.7% | 9% drawdown

ConocoPhillips prints a 4.8% FCF yield, a 2.7% dividend yield, and a 13.4% ROIC, with 51% payout cover (FCF yield divided by dividend yield of 1.77). Revenue growth runs at 7.7% year-over-year, and the company carries 0.72× net debt/EBITDA, a clean balance sheet for a major independent.

Three executives bought shares in the last 30 days: Mauricio Botero Wolff and Jose Mauricio Rodriguez Rios on March 30, Jorge Humberto Hernandez on April 7. The three transactions total 261,521 net shares purchased, a $32.4 million insider commitment at current prices.

The stock trades 9% below its 52-week high, but the one-year trend is flat (0.06%). The market is pricing in oil-price risk and macro uncertainty; analyst targets at $131 (5.7% upside) reflect subdued conviction until WTI stabilizes above $80.

RBC raised its target to $152, Piper Sandler to $157, but those forecasts assume sustained $85+ WTI and no OPEC+ supply surprises. If demand softens or geopolitical risk premiums compress, ConocoPhillips' free cash flow yield will narrow, and the dividend cover will tighten.

5. General Dynamics Corporation (GD)

Stock Pixie Score 8.0/10 | FCF yield 4.2% | Revenue growth 10.1% | 6% drawdown

General Dynamics delivers a 4.2% FCF yield, 10.1% revenue growth, and a 13.2% ROIC, with a 1.75% dividend yield covered by solid free cash flow (payout cover 2.4×). Net debt/EBITDA sits at 1.18, manageable for a defense prime with $13.7 billion in interest coverage and a $108 billion backlog.

Three insiders purchased shares on March 11: CFO Gregory Gallopoulos, Senior VP Catherine Reynolds, and VP Peter Wall. The three transactions total 192,340 net shares acquired, a $66.8 million bet at current prices, the largest insider purchase on this week's screen.

Deutsche Bank downgraded the stock to Hold this week, citing valuation concerns at 22.5× P/E and 16× EV/EBITDA. The firm argues that defense multiples have run ahead of earnings growth, and upside catalysts are priced in until the next budget cycle delivers incremental contract wins.

Analyst targets at $393.79 imply 13.4% upside, but that forecast assumes sustained defense-budget expansion and no delays in the Columbia-class submarine program or Gulfstream business-jet deliveries. If Congress trims appropriations or commercial aerospace demand softens, the stock will re-rate lower.